The EWS/FLI1 fusion gene is well-characterized as a driver of Ewing's sarcoma. Bi-shRNA
EWS/FLI1 is a functional plasmid DNA construct that transcribes both siRNA and miRNA-like …

The EWS/FLI1 fusion gene is well characterized as a driver of Ewing's sarcoma. Bi-shRNA
EWS/FLI1 is a functional plasmid DNA construct that transcribes both siRNA and miRNA-like …

The EWS/Fli‐1 fusion gene, a product of the translocation t (11; 22, q24; q12), is detected in
85% of Ewing sarcomas and primitive neuroectodermal tumors. It is thought to be a …

Existing data identify EWS–FLI1 as indispensable for sustained Ewing's sarcoma growth
and as the ideal therapeutic target in this disease. The siRNA may hold great promises as a …

Ewing sarcoma (ES) is a highly aggressive cancer of the bone and soft tissue. In∼ 85% of
ES tumors the primary oncogenic event is at (11: 22)(q24: q12) translocation that generates …

Ewing's sarcoma tumors are associated with chromosomal translocation between the EWS
gene and the ETS transcription factor gene. These unique target sequences provide …

Abstract 6104 Despite aggressive therapy, 40% of patients with localized Ewing's family
tumors (EFT) and 80% with metastasis die due to tumor progression. More specific and …

70. Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral
Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma × Close …

The EWS-Fli1 fusion gene, resulting from at (11; 22) translocation, plays a key role in the
Ewing's sarcoma pathogenesis. In the past, a 25mer phosphorothioate antisense …

The development of effective, systemic therapies for metastatic cancer is highly desired. We
show here that the systemic delivery of sequence-specific small interfering RNA (siRNA) …